Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
DS-3939 by Glycotope for Metastatic Ovarian Cancer: Likelihood of Approval
DS-3939 is under clinical development by Glycotope and currently in Phase II for Metastatic Ovarian Cancer. According to GlobalData, Phase...
DS-3939 by Glycotope for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
DS-3939 is under clinical development by Glycotope and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According to...
DS-3939 by Glycotope for Metastatic Biliary Tract Cancer: Likelihood of Approval
DS-3939 is under clinical development by Glycotope and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...
DS-3939 by Glycotope for Metastatic Breast Cancer: Likelihood of Approval
DS-3939 is under clinical development by Glycotope and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase...
DS-3939 by Glycotope for Non-Small Cell Lung Cancer: Likelihood of Approval
DS-3939 is under clinical development by Glycotope and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
DS-3939 by Glycotope for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
DS-3939 is under clinical development by Glycotope and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
DS-3939 by Glycotope for Solid Tumor: Likelihood of Approval
DS-3939 is under clinical development by Glycotope and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...